MX2025014082A - Cristal de compuesto heterociclico que contiene nitrogeno que tiene un efecto de activacion del factor 2 relacionado con el factor nuclear eritroide 2 (nrf2) - Google Patents
Cristal de compuesto heterociclico que contiene nitrogeno que tiene un efecto de activacion del factor 2 relacionado con el factor nuclear eritroide 2 (nrf2)Info
- Publication number
- MX2025014082A MX2025014082A MX2025014082A MX2025014082A MX2025014082A MX 2025014082 A MX2025014082 A MX 2025014082A MX 2025014082 A MX2025014082 A MX 2025014082A MX 2025014082 A MX2025014082 A MX 2025014082A MX 2025014082 A MX2025014082 A MX 2025014082A
- Authority
- MX
- Mexico
- Prior art keywords
- crystal
- compound
- nitrogen
- activation effect
- heterocyclic compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023100075 | 2023-06-19 | ||
| PCT/JP2024/022040 WO2024262491A1 (ja) | 2023-06-19 | 2024-06-18 | Nrf2活性化作用を有する含窒素複素環化合物の結晶 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2025014082A true MX2025014082A (es) | 2026-01-07 |
Family
ID=93935419
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025014082A MX2025014082A (es) | 2023-06-19 | 2025-11-25 | Cristal de compuesto heterociclico que contiene nitrogeno que tiene un efecto de activacion del factor 2 relacionado con el factor nuclear eritroide 2 (nrf2) |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4696692A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7904995B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20260023529A (cg-RX-API-DMAC7.html) |
| CN (1) | CN121152792A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2024314540A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL324833A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2025014082A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202504613A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2024262491A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6326507B1 (en) | 1998-06-19 | 2001-12-04 | Trustees Of Dartmouth College | Therapeutic compounds and methods of use |
| TWI649330B (zh) | 2013-04-24 | 2019-02-01 | 艾伯維有限公司 | 甲基巴多索龍之2,2-二氟丙醯胺衍生物、其多晶形及其使用方法 |
| US20190380992A1 (en) | 2014-12-04 | 2019-12-19 | Biogen Ma Inc. | Multiple Sclerosis Treatment Regimen Using Dimethyl Fumarate |
| JP2020097526A (ja) * | 2017-03-28 | 2020-06-25 | 武田薬品工業株式会社 | 複素環化合物 |
| JOP20210030A1 (ar) | 2018-08-20 | 2021-02-16 | Janssen Pharmaceutica Nv | مثبطات تفاعل البروتين-بروتين KEAP1-Nrf2 |
| KR102932313B1 (ko) | 2019-02-15 | 2026-02-26 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Nrf2 활성화제로서 히드록시피리드옥사제핀 |
| CN114174289B (zh) | 2019-05-31 | 2025-03-07 | Ube株式会社 | 苯并三唑衍生物 |
| GB202005852D0 (en) | 2020-04-22 | 2020-06-03 | C4X Discovery Ltd | Therapeutic compounds |
| CN114507181B (zh) | 2020-11-17 | 2024-03-26 | 中国医学科学院药物研究所 | 含5-取代四氢异喹啉的丙酸类化合物、其药物组合物和应用 |
| CR20240325A (es) | 2022-01-07 | 2024-11-22 | Chugai Pharmaceutical Co Ltd | Compuesto heterocíclico que contiene nitrógeno que tiene un efecto de activación del nrf2 |
-
2024
- 2024-06-18 EP EP24825892.3A patent/EP4696692A1/en active Pending
- 2024-06-18 AU AU2024314540A patent/AU2024314540A1/en active Pending
- 2024-06-18 TW TW113122470A patent/TW202504613A/zh unknown
- 2024-06-18 KR KR1020257042624A patent/KR20260023529A/ko active Pending
- 2024-06-18 CN CN202480033461.0A patent/CN121152792A/zh active Pending
- 2024-06-18 IL IL324833A patent/IL324833A/en unknown
- 2024-06-18 WO PCT/JP2024/022040 patent/WO2024262491A1/ja not_active Ceased
- 2024-06-18 JP JP2025528066A patent/JP7904995B2/ja active Active
-
2025
- 2025-11-25 MX MX2025014082A patent/MX2025014082A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202504613A (zh) | 2025-02-01 |
| JP7904995B2 (ja) | 2026-08-13 |
| IL324833A (en) | 2026-01-01 |
| AU2024314540A1 (en) | 2025-11-27 |
| KR20260023529A (ko) | 2026-02-20 |
| EP4696692A1 (en) | 2026-02-18 |
| JPWO2024262491A1 (cg-RX-API-DMAC7.html) | 2024-12-26 |
| CN121152792A (zh) | 2025-12-16 |
| WO2024262491A1 (ja) | 2024-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20220251A (es) | Nuevos derivados de metilquinazolinona | |
| SG11201804121RA (en) | Novel biphenyl compound or salt thereof | |
| SA521422143B1 (ar) | 15-pgdh مثبط | |
| EA202192138A1 (ru) | Гетероциклическое соединение и его применение | |
| EA202091479A1 (ru) | Арил- и гетероарилзамещенные индольные соединения | |
| MX391414B (es) | Compuesto novedoso de bifenilo o sal del mismo. | |
| AU2018312326A2 (en) | Heterocyclic compound and use thereof | |
| MX2019010261A (es) | Derivados de oxadiazol microbicidas. | |
| EP4474017A3 (en) | New heterocyclic compounds | |
| BR112022001191A2 (pt) | Combinações fungicidas, misturas e composições e usos das mesmas | |
| EA202091477A1 (ru) | Замещенные соединения простых индольных эфиров | |
| EA201992320A1 (ru) | Пиперидины в качестве ковалентных ингибиторов менина | |
| MX2022008665A (es) | Nuevo derivado de pirazol. | |
| WO2021053402A3 (en) | Sulfonamide derivatives as ctps1 inhibitors | |
| PH12018502513A1 (en) | Sulfonamide compound or salt thereof | |
| MX2021004474A (es) | Compuestos que contienen deuterio. | |
| MX2020005077A (es) | Compuestos con acción estabilizadora, procedimiento para su preparación, composición que contiene estos compuestos estabilizadores, procedimiento para la estabilización de un componente orgánico así como uso de compuestos estabilizadores. | |
| MX388175B (es) | Compuestos terapéuticos y métodos para utilizarlos | |
| MX2021003427A (es) | Nuevos oxadiazoles. | |
| UY38941A (es) | Nuevas sulfiliminas o sulfoximinas que contienen compuestos heterocíclicos fungicidas | |
| EA202192134A1 (ru) | Амидзамещенные гетероциклические соединения | |
| MX2020012760A (es) | Nuevos compuestos de piridina y pirazina como inhibidores del receptor cannabinoide 2. | |
| EP4706394A3 (en) | Use of alkoxypyrazoles as nitrification inhibitors | |
| MX2020001615A (es) | Compuestos de piridina sustituidos con azol. | |
| MX2019014406A (es) | Compuesto heterociclico y composicion que contiene el mismo. |